GLPwatch
Efficacy and safety of orforglipron in type 2 diabetes mellitus and obesity: a GRADE-assessed meta-analysis and trial sequential analysis with subgroup evaluations by diabetic status, obesity status, and dose regimens.
Acta Diabetol · 2026
Last updated 2026-05-28| Journal | Acta Diabetol, 2026 |
|---|---|
| Citations | 2 |
| Molecules | orforglipron |
| Conditions studied | Type 2 Diabetes, Obesity |
Full record and abstract on PubMed 41498807 ↗
Related research
- Daily Oral GLP-1 Receptor Agonist Orforglipron for Adults with Obesity.
- Efficacy and safety of oral orforglipron in patients with type 2 diabetes: a multicentre, randomised, dose-response, phase 2 study.
- Orforglipron, an Oral Small-Molecule GLP-1 Receptor Agonist, in Early Type 2 Diabetes.
- Orforglipron, an Oral Small-Molecule GLP-1 Receptor Agonist for Obesity Treatment.
- Orforglipron (LY3502970), a novel, oral non-peptide glucagon-like peptide-1 receptor agonist: A Phase 1b, multicentre, blinded, placebo-controlled, randomized, multiple-ascending-dose study in people with type 2 diabetes.
- Orforglipron (LY3502970), a novel, oral non-peptide glucagon-like peptide-1 receptor agonist: A Phase 1a, blinded, placebo-controlled, randomized, single- and multiple-ascending-dose study in healthy participants.
- The pharmacological basis for nonpeptide agonism of the GLP-1 receptor by orforglipron.
- Orforglipron, a novel non-peptide oral daily glucagon-like peptide-1 receptor agonist as an anti-obesity medicine: A systematic review and meta-analysis.